Introduction: Pharmacotherapy has a pivotal role in the management of endometriosis with
long-term treatments balancing clinical efficacy (control of pain symptoms and prevention of …

Endometriosis currently affects∼ 5.5 million reproductive-aged women in the US with
symptoms such as painful periods (dysmenorrhea), chronic pelvic pain, pain with …

Objective: Endometriosis affects up to 10% of women of reproductive age, and the main goal
of treatment is to relieve symptoms. Progestins have been the mainstay of endometriosis …

Endometriosis can recur after either surgical or medical therapy. Long-term medical therapy
is implemented to treat symptoms or prevent recurrence. Dienogest and gonadotropin …

Objective To assess the proportion of patients satisfied with their treatment before and after a
systematic change from norethindrone acetate to dienogest as the first-line progestin for …

Purpose Endometriosis is a debilitating disease with high recurrence rates requiring long-
term management. Progestins such as dienogest are used empirically when first symptoms …

Introduction: Endometriosis is a chronic estrogen and progestogen responsive inflammatory
disease associated with pain symptoms and infertility. The medical therapy of endometriosis …

Endometriosis is a chronic disease that requires a suitable, lifelong treatment. To our
knowledge, the Vi sanne P ost-approval O bservational S tudy (VIPOS) is to date the largest …

Abstract Nuclear receptor 4A1 (NR4A1) plays an important role in endometriosis
progression; levels of NR4A1 in endometriotic lesions are higher than in normal …

Studies have been published on the efficacy of Dienogest in the management of pain
symptoms in endometriosis. Nonetheless, few data are available on the reducing effect on …